A Case of Therapy-related Acute Myeloid Leukemia associated with inv(16)

So-Young Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Sung Yong Kim; Hee Je Kim; In-Yang Park

doi:10.3343/kjlm.2007.27.1.19

Journal List > Korean J Lab Med > v.27(1) > 1011391

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee, Kim, Lim, Kim, Han, Kim, Kim, and Park: A Case of Therapy-related Acute Myeloid Leukemia associated with inv(16)

Original Article

Korean J Leg Med 2007;27(1):19-21.

Published online: 10 February 2007

DOI: https://doi.org/10.3343/kjlm.2007.27.1.19

A Case of Therapy-related Acute Myeloid Leukemia associated with inv(16)

So-Young Lee, M.D.¹, Myungshin Kim, M.D.¹, Jihyang Lim, M.D.¹, Yonggoo Kim, M.D.¹, Kyungja Han, M.D.¹, Sung Yong Kim, M.D.², Hee Je Kim, M.D.², In-Yang Park, M.D.³

¹Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

²Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

³Department of Obstetrics & Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea

Received 14 June 2006 Revised 4 December 2006 Accepted 6 December 2006

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The inv(16)(p13q22) is found in de novo AML and is closely associated with the FAB subtype M4eo. The inv(16) is rarely reported in therapy-related AML (t-AML) patients. Herein, we report a case of t-AML with inv(16) after combination chemotherapy using antimitotic agent and alkylating agent (cis-platin-paclitaxel) for ovarian serous cystadenocarcinoma.

Keywords: Therapy-related AML, Inv(16), Alkylating agents, Antimitotic agent

References

1. Jaffe ES, Harris NL, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissue. France: IARC Press, Lyon;2001. p. 82–4. 89–91.

2. Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pederson-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002; 33:395–400.

3. Yoon T, Kim DY, Lee KW, Kim DH, Yoon SS, Park SY, et al. A case of therapy-related acute lymphoblastic leukemia after 131 I-treatment for thyroid papillary carcinoma. Korean J Med. 2004; 66:437–41.

4. Song SH, Bin JS, Kim JH, Park YS, Park KC, Shun DJ, et al. Therapy-related acute myelogenous leukemia with complex chromosomal defect. Report of a case. Korean J Hematol. 1992; 27:117–22.

5. Kim M, Lim J, Kim Y, Han K, Kang CS, Kim HJ, et al. A case of therapy-related acute myeloid leukemia associated with inv(16), with subsequent development of t(9;22). Leukemia. 2006; 20:746–8.

6. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003; 21:897–906.

7. Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors? J Clin Oncol. 1998; 16:1890–6.

Fig. 1.

Bone marrow aspirate smear (× 1,000, Wright stain).

Fig. 2.

Karyotype analysis: 47,XX,inv(16)(p13.1q22),+22 [20].

Fig. 3.

FISH analysis with LSI 5′ CBFβ (Red)/ LSI 3′ CBFβ (Green) dual color, break apart rearrangement probe (Vysis, Inc). Normal chromosome 16 showed overlapping red/green signals (green arrow) and abnormal chromosome 16 split the CBFβ locus resulting in separate red and green signals (white arrow).

TOOLS

Similar articles